Bionova Scientific, Inc.

Bionova Scientific, Inc. is a biotechnology company focused on developing and manufacturing biologics, specifically recombinant protein therapeutics, to improve the biopharmaceutical landscape. Founded in 2014 by Chung Chun and Amy Kong, Bionova Scientific, Inc. is headquartered in Fremont, US.

The company specializes in biologics production and has undergone significant growth, evidenced by its recent acquisition by Asahi Kasei Corporation in April 2022. Bionova has engaged in 2 investment deals, with the latest funding round being a Growth round in which the company raised USD 13. 30 mn from Great Point Partners, totaling USD 13. 30 mn raised overall.

Bionova specializes in the development and manufacturing of biologics, particularly recombinant protein therapeutics such as monoclonal antibodies (mAbs) and other therapeutic proteins. Utilizing advanced mammalian cell culture processes, Bionova delivers solutions to expedite time to market for biopharmaceuticals, addressing critical challenges within the therapeutic landscape. Their services cover the entire product lifecycle, from early cell line development to commercial biomanufacturing, ensuring clients receive robust and scalable solutions tailored to their specific needs. Their primary clientele includes biopharmaceutical companies across North America, Europe, and Asia, leveraging top scientific talent and state-of-the-art infrastructure.

Bionova generates revenue through B2B partnerships with biopharmaceutical companies, engaging clients under service agreements that encompass various developmental and manufacturing processes, including contract development and manufacturing organization (CDMO) services. These agreements typically involve milestone-based payments contingent on specific project deliverables, promoting long-term partnerships and ongoing collaboration. Notable offerings include proprietary technologies and methodologies designed to enhance biomanufacturing efficiency, with specific pricing determined case-by-case based on client needs and project scope. Bionova Scientific, Inc.

plans to expand its product offerings and enter new markets, specifically targeting biopharmaceutical sectors in Europe and Asia by 2024. The recent funding of USD 13. 30 mn raised in April 2022 will support the development of new biologics and enhance their manufacturing capabilities. The company's strategy is further defined by its acquisition by Asahi Kasei Corporation, which is expected to provide additional resources for growth and innovation in the biologics space.